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EDITORIALBeneﬁt of Catheter-directed Thrombolysis for Acute Iliofemoral DVT: Myth
or Reality?Anticoagulation, alone, does not reduce the overall
thrombus burden following deep venous thrombosis (DVT).
Accordingly, chemical, surgical and mechanical strategies
have been developed for removing thrombus, rather than
leaving it in situ. The history of thrombolysis dates back
40e50 years and several thrombolytic protocols have been
developed as alternatives to surgical thrombectomy. Sys-
temic thrombolysis was abandoned because of its limited
success, with only 45% of acute DVT patients achieving
signiﬁcant or complete clearing of thrombus, compared
with only 4% after anticoagulation (AC) alone.1 Regional
intravenous thrombolysis has been utilized in combination
with surgical thrombectomy in general anaesthesia.2 The
most interesting, recent breakthrough in DVT treatment has
been the introduction of intra-thrombus catheter-directed
thrombolysis (CDT) for acute clot removal, followed by
additional stenting if indicated. This technique was ﬁrst
described in 19913 and has primarily been used for the
treatment of acute iliofemoral DVT. The rationale for
delivering the thrombolytic agent directly into the
thrombus is the protection of plasminogen activator from
neutralization by circulating plasminogen activator in-
hibitors, and it also protects plasmin from neutralization by
alfa-2-antiplasmin.1
Although most patients with acute DVT are still treated
by AC alone, the search for new treatment strategies has
been driven by awareness of the extremely troublesome
and disabling symptoms associated with post-thrombotic
syndrome (PTS). PTS can develop within 1 month of
suffering an acute DVT and almost half of DVT patients will
develop PTS within 2 years of the acute thrombosis.
Perhaps, not surprisingly, proximally located thromboses
are associated with poorer outcomes.4 The underlying
pathophysiological mechanisms associated with PTS include
outﬂow obstruction at the iliofemoral level and/or distal
valvular incompetence, which can result in venous claudi-
cation, symptoms and signs of chronic venous insufﬁciency,
and eventually venous ulceration. The alleged positive
beneﬁt of compression stockings for preventing PTS was
challenged in a recently published RCT,5 once again
emphasizing the need for a more targeted approach to
treatment: namely, get rid of the thrombus before it can
harm the vein.
Over the last decade, numerous case series, single cen-
ter- and multicenter studies, comparative studies, and a few
RCTs have evaluated the role of CDT. A recent meta-analysis,
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Surgery. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2014.04.032CDT with AC for the treatment of iliofemoral DVT. Despite a
relatively small number of patients and heterogeneous
endpoints, CDT (compared with AC) signiﬁcantly reduced
the risk of residual obstruction (RR 0.38 [95% CI 0.18e0.37])
and PTS (RR 0.19 [95% CI 0.07e0.48]).6
The long-term results of the Norwegian CaVenT trial
(which randomized 209 patients to either CDT/AC or AC
alone) were published in 2012.7 After 24 months, data on
PTS were available for 189 DVT patients (90 treated with
CDT/AC versus 99 treated by AC only). In the CDT/AC group,
37 patients (41.1%) presented with PTS, compared with 55
(55.6%) in the control group (p ¼ .047), corresponding to an
absolute risk reduction of 14.4% (95% CI 0.2e27.9). The
border-line p value implies a somewhat moderate inter-
group difference. This could, however, be explained by se-
lection bias as only half of the randomized patients had a
DVT involving the iliac segment. Patients with thrombus at
the iliac level would, in all likelihood, beneﬁt more from
CDT with stenting of any iliac obstructive lesions, especially
the left common iliac vein. Further subgroup analyses
showed that CDT treatment appeared to be cost-effective,8
but quality of life (QOL) was not different between the
two groups after 24 months.9 However, patients with PTS
had a much poorer QOL than did patients without PTS
(p < .001).9
So what can be deduced from the Norwegian RCT? First
of all, it is important to remember that the spontaneous
natural history of DVT differs according to the involved
venous segment(s). Partial or complete recanalization of the
femoral segment is seen in almost 80% of patients after 6
months.10 The iliofemoral segment, on the other hand, will
only recanalize in 20% of cases at 5 years.11 This emphasizes
the importance of delivering CDT to that part of the venous
system, which is considered to be the outﬂow tract for the
entire limb. Furthermore, CDT is effective in reducing the
incidence of PTS.
Results from Copenhagen underscore the potential long-
term beneﬁt of CDT. In a prospective study in 109 patients
with iliofemoral DVT treated with CDT and additional
stenting (where indicated), only 16% of patients developed
PTS after a mean follow-up of 71 months. Patients with
competent veins had signiﬁcantly higher QOL than did pa-
tients with valvular incompetence.12
The US multicenter registry study from 1999, which
included 221 limbs with iliofemoral DVT treated by CDT and
additional iliac vein stent placement in 99 (45%), showed
that the 12-month patency of the lysed segment varied
signiﬁcantly between stented limbs (74%) and those that
were not stented (53%) (p < .001).13 These data suggest
that stenting the iliac vein should be considered in the
majority of cases. In the CaVenT study, stenting of the
362 Editorialiliac venous segment was performed in only 18% of cases. A
further 26% underwent balloon angioplasty alone, which is
most likely to fail in the venous system. In the Copenhagen
series, almost 60% of cases were stented.14 Recently, new
data with ultrasound accelerated thrombolysis have been
presented, in which 83% were treated with iliac stenting.15
CDT is an accessible and successful method of achieving
thrombus removal in acute iliofemoral DVT, and stenting
should be considered mandatory in more than 50% of
cases. The results from the Norwegian CaVenT study should
not bring CDT into disrepute. Centers with an interest in
CDT should optimize inclusion criteria and technical aspects.
Furthermore, the 2-year follow-up from the American
ATTRACT trial and the 1-year data from the Dutch CAVA
trial, both comparing CDT (with additional stenting) with
anticoagulation alone are not yet available.16,17 In these
two trials, limbs are stratiﬁed according to the involved
venous segments, that is primarily to the iliofemoral level,
but the ATTRACT Study will also stratify according to the
femoropopliteal level. Additive mechanical devices for
shortening treatment time are also being tested.
Hopefully, the results from these randomized trials (due
in 3e4 years time) will provide greater clarity regarding the
role of CDT, based on strict stratiﬁcation of patients ac-
cording to which venous segments are involved.
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